Abstract: A recent search on PubMed for the phrase NMDA receptor results in 2,190 hits on this topic for review articles and 20,100 hits for experimental papers. This is a direct reflection of the intensiveness, significance, and complexity associated with the research on this key receptor protein over the last several decades. In this review, we briefly describe the NMDA receptor structure, discuss the role of NMDA receptors in modulating synaptic plasticity and excitotoxicity, explore age-dependent changes in NMDA receptor functioning, and survey interesting NMDA receptor blockers. Given the huge existing literature on the subject, an exhaustive review has not been endeavored. Instead, an attempt was made to point out those studies that have been instrumental in the field or that are of special interest.
INTRODUCTION
Past work involving the N-Methyl-D-aspartic acid (NMDA) receptor ( Fig. 1) has had its ups and downs, so to speak. There of course has been much advancement. Research concerning the origins, development, and function of the NMDA receptor over the last 25 years has been well documented [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . In addition, characteristics of the NMDA receptor complex have also been well described with regard to biophysical properties and the molecular biology of the receptor-ion complex [10] . Moreover, downstream events resulting from the activation of the NMDA receptor has also been actively investigated, and studies have shown that small molecules such as glutamate are capable of inducing significant conformational changes in the NMDA receptor protein leading to the initiation and/or maintenance of vital cellular functions [11] . To this end, the NMDA receptor has been shown to play a role in a number of diverse, but essential biological processes, such as synaptic integration and plasticity, development, and memory, to name a few [12] [13] [14] [15] . Closely aligned with these observations, key studies have also shown that the NMDA receptor is activated in a variety of disease processes and conditions, including acute brain injury (stroke and trauma), epilepsy, Alzheimer's disease, chronic motor disorders, pain, and schizophrenia [16, 17] . Collectively, these studies led to an important basic understanding of the NMDA receptor in normal neurobiology and also during excitotoxic conditions. Given these vital roles in the cell, many academic studies and industrial drug discovery/development programs investigated agonists and antagonists of the NMDA receptor complex over the last 25 years where structure-activity, molecular modeling, and other related investigations were accomplished. In fact, billions of dollars have been spent over this time frame and tremendous effort has been exerted with the hope of using NMDA antagonists to block pathological activity initiated by NMDA receptor activation. Unfortunately, in spite of early preclinical work showing the promise of NMDA antagonists in limiting acute injury, it was quickly realized that first generation NMDA blockers were associated with serious side effects, which included hallucinations, developmental abnormalities, and even coma [18] [19] [20] . From these setbacks it was recognized that not only was too much NMDA activity harmful to neurons, but so was too little NMDA activity where excessive blockade of the NMDA receptor appears to interfere with essential functioning and cell survival signaling [21] . However, the direction of NMDA drug targeting research has taken yet another turn and more recent reports with compounds such as memantine have demonstrated that there is still a strong rationale for blocking NMDA receptor activation, but that more clever approaches are necessary [22, 23] . Other examples also exist, and advances in the development of selective NMDA receptor subtype antagonists are also being investigated [24] . In this review, we describe the structure of NMDA receptor complex, discuss the role of NMDA receptors in modulating synaptic plasticity and excitotoxicity, explore NMDA receptor functioning in developmental and aging contexts, and survey the discovery and development of past and present NMDA receptor blockers, which are again showing promise for treating acute and chronic neurological conditions. In so doing we do not attempt an exhaustive search of the literature since many excellent reviews have already been published on many facets of the NMDA receptor. In fact, a search on PubMed for NMDA receptor results in 2,190 hits for review articles and 20,100 hits for experimental papers. Instead, an attempt is made to point out those studies that have been instrumental in the field or that are of special interest. We apologize to those investigators that were not included, but this has no bearing on the quality or importance of these prior studies. Fig. (1) . NMDA receptor/ion complexes. NMDA receptors, also classified as transmembrane proteins, are found throughout the plasma membrane of the cell. In the hippocampus, a region instrumental in both synaptic plasticity and excitotoxic events, NMDA receptors are concentrated in the postsynaptic specialization where this region coincides with the postsynaptic density. The current model of the composition of the NMDA receptor suggests that these complexes assemble in tetramers from two subunits, ie., NR1 (red) and NR2 (blue).
THE NMDA RECEPTOR COMPLEX NMDA Receptor Subunits
The NMDA receptor is assembled from combinations of NR1 and NR2A-D, and in some cases, NR3A or B subunits [25] . The NR1 subunit is encoded from one gene [26] ; currently, it is known that there are eight different NR1 splice variants [26, 27] . The NR2 subunits (2A-D) are encoded by four different, but closely related genes [26, 28] .
NMDA subunits have specific regional expression patterns [10, 12] . Rodent cortex contains primarily NR1, NR2A, and NR2B subunits, whereas the cerebellum shows a high expression of NR2C [10] . Studies of human NMDA receptor subunit expression have been much more limited, but some reports claim similar, but not identical expression patterns to rat for NR1, NR2A, and NR2B [29] . Evidence also suggests that the NMDA receptor complex is typically composed of a tetramer of NR1 and NR2 subunits (usually two NR1 and two NR2 subunits) where the presence of the NR1 subunit is mandatory, however many other combinations are also possible [27, 30] . In fact, a majority of the literature now suggests that functional NMDA receptor complexes are tetramers composed of two dimers, ie., two NR1 and two NR2 subunits [31] .
Subunit Functionality
Various studies have also shown that each subunit or specific subunit combinations convey distinct properties [30] . For example, the NR1 subunit binds glycine (or D-serine), whereas the NR2 subunit is a site that binds glutamate [27] . However, the glycine site must be occupied before glutamate can activate the receptor and data suggest that the glycine site might be occupied most of the time [32] . Probably one of the most well known functional aspects is that combinations of NR1 and NR2 form a channel that is permeable to calcium ions [33] . However, at rest the NMDA channel is blocked by Mg ++ ions, thus blocking calcium, but upon sufficient depolarization the Mg ++ block is alleviated in a voltage-dependent manner [2, 22] . The NMDA channel is also permeable to Na + and K + ions [25] . NMDA receptors that contain NR2A or NR2B subunits also give rise to high-conductance channel open probabilities [34] . NMDA receptors containing NR2C or NR2D, on the other hand, appear to produce low-conductance channel openings [34] . NR3 subunits can also assemble with NR1, to form a glycine receptor or assemble with NR1-NR2 complexes, which can depress NMDA responses [35, 36] . Moreover, the pH sensitivity of the NMDA receptor is determined by the presence of exon 5 where the exon 5 cassette forms a surface loop that acts as a modulator to shield the proton sensor of NR1 [34] . Interestingly, NR2 subunits do not migrate to the cell membrane unless they associate with NR1 subunits and regions of the N-terminus of NR1 appear critical for subunit association [26] .
Topology
Several binding sites and an overall membrane topology have been described for the NMDA receptor (Fig. 2) . The N-terminal domain is extracellular and can be modulated by protons or spermine [25, 36] . Four transmembrane domains also exist (M1-M4) where the so-called selectivity filter of the NMDA channel is located on M2 (a P-loop region) [25] . Ligand-binding domains are formed by S1 and the M3-M4 linker region, S2. A cytoplasmic Cterminal domain is also present and interacts with key intracellular signaling proteins [25, 36] .
Mutations in NMDA Receptor Subunits
Several NMDA receptor mutant mouse models have been engineered over the years to determine the effect of genetic alterations on NMDA receptor function, synaptic plasticity, and learning and memory, etc. For example, transgenic mouse models (NR1 K483Q and NR1 D481N mutations) have been created for studying how modulations in glycine affinity for the NMDA receptor affects NMDA receptor function [37] . In short, these models have shown that the glycine binding site is critical for normal NMDA function since homozygous K483Q mutants die early after birth and D481N mutants have reduced long-term potentiation (LTP), a cellular model of memory encoding and impaired acquisition in the Morris water maze, a test for spatial memory [37] . Other point mutations in the NR1 subunit have also been engineered and specifically for the asparagine residue in the M2 segment (N598), which determines calcium permeability in the NMDA channel [38] . In one investigation, aspargine was changed to glutamine (Q) or arginine (R) and these mice either died perinatally (ie., Q/Q or -/R strains) or showed reduction in calcium permeability in electrophysiological recordings from nucleated patches of CA1 cells of hippocampal slices.
Studies have also been conducted in NR2 mutant mice. For example, adult NR2A knockout mice were reported to have significant reductions in NMDA-mediated synaptic currents in CA1 neurons, however CA1 LTP and spatial learning were only slighted impaired suggesting that NR1/NR2B combinations are probably sufficient for adult synaptic plasticity and memory functions [39] . On the contrary, NR2B knockout mice die shortly after birth given a deficiency in the suckling response. When the mice are hand-fed, synaptic NMDA currents and CA1 LTD responses were blocked, suggesting that the NR2B subunit is necessary for synaptic plastic- Fig. (2) . Binding Sites. Several important binding sites are depicted (but not exclusive).
ity and memory during early development [40] . Interestingly, when mice were engineered to have forebrain-specific overexpression of the NR2B gene (driven by the -CaMKII promoter), they showed increased CA3 LTP and enhanced associative learning and memory, which was hypothesized to be due to increased channel open time [41] .
ROLE OF NMDA RECEPTORS IN SYNAPTIC PLASTICITY Activation of the NMDA Receptor
Activation of the NMDA receptor requires the binding of both glutamate and glycine along with simultaneous depolarization of the cell membrane [2] . NMDA receptor activation and NMDAmediated downstream signaling appear essential for normal synaptic function [2] . Hippocampal synaptic plasticity in most cases depends on both NMDA receptor activation and calcium influx [42] . The current and most widely accepted model of synaptic plasticity that results in long-term synaptic change involves the experimental paradigms of long-term potentiation (LTP) and long-term depression (LTD) [15, [43] [44] [45] . NMDA receptor activation has also been shown to trigger an additional release of calcium from intracellular stores [46] . Since calcium entry occurs through the NMDA receptor ion complex only if there is simultaneous presynaptic glutamate release and postsynaptic membrane depolarization, the NMDA receptor has been termed a synaptic coincidence detector [47] . Compared to amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, which are typically colocalized with NMDA receptors, NMDA receptors have slower activation kinetics, longer channel open times, and higher affinities to glutamate [28] . The influx of calcium, a second messenger, transduces NMDA receptor activation into calcium-dependent intracellular signaling via a variety of different pathways, including NMDA-dependent pathways of synaptic plasticity.
Synaptic Plasticity and NMDA Receptors
A substantial number of in vitro and in vivo studies have shown that in LTP brief bursts of high frequency electrical stimulation (~100 Hz) lead to a long-lasting increase in the strength of synaptic transmission, whereas prolonged low frequency stimulation (~1 Hz) results in a persistent reduction in synaptic transmission, where stimulation protocols are meant to simulate endogenous conditions of membrane depolarization [15, 42, 45] . As a result of this depolarization, several neurochemical processes are initiated. For example, both LTP and LTD are associated with an increase in intracellular calcium ([Ca ++ ] i ) [17] ; however, LTD is associated with smaller increases (~750 nM for ~ 1 min) of [Ca ++ ] i than LTP (>10 μM for 5-6 secs) [48] . Johnston and colleagues using calcium imaging techniques showed that LTP at all major hippocampal synapses share a common induction mechanism involving an initial rise in postsynaptic [Ca ++ ] [49] . It is generally accepted that the rise in postsynaptic [Ca ++ ] required for CA1 hippocampal LTP induction is due to the entry of Ca ++ via the NMDA receptor complex [50] , although other Ca ++ sources do have an effect under different conditions or in different compartments (egs., dendritic spines, aging, mossy fiber synapses [51, 52] ). Typically, there are four routes for calcium entry into the cytosol (ie., NMDA, AMPA, VDCC, or release from intracellular stores) [53] . Under physiological conditions, the induction of LTP is typically controlled then by the NMDA receptors, whereas the expression and maintenance of LTP, has multiple mechanisms, including AMPA receptors. Many excellent reviews have been written on the biophysics and neurochemical aspects associated with these time-dependent phases of LTP induction, expression, and maintenance [15, 42, 45, 54] .
Regulation of NMDA Receptors by Kinases and Phosphatases
The post-translational regulation of the NMDA receptor by kinases or phosphatases, which function in opposition to each other, have been shown to play an important role in synaptic transmission and synaptic plasticity by providing signaling feedback to the NMDA receptor and other receptors [55] [56] [57] . In fact, studies show that the initiation of either kinase or phosphatase activity specifically regulates the form of synaptic plasticity expressed (see reviews [56, 58, 59] ). One to five Hz electrical stimulation, typically used for the generation of LTD responses, activates protein phosphatases, whereas 25-100 Hz stimulation, utilized for LTP response generation, activates protein kinases. Mechanisms for regulation of receptor function by kinases or phosphatases have been described that include the phosphorylation or dephosphorylation of sites on glutamatergic receptors, which result in changes in ion flux permeability though these channels and/or other changes.
In particular, PKC, PKA, casein kinase, Src kinases and phosphatases, and calcium/calmodulin-dependent kinases and phosphatases, have all been shown to regulate NMDA receptor function (see review [57] ). For example, one indirect consequence (via CAK /Src tyrosine kinase cascade) of PKC activation is the enhancement of NMDA receptor activation, which also may increase the number of NMDA receptors expressed in synapses. In addition, direct phosphorylation of NMDA receptors by PKC increases the sensitivity of NMDA channel inactivation to [Ca ++ ] i . Potential sites for phosphorylation by PKC exist on NMDA receptors and many of these have been found to be specifically located in the C-terminus region of the NR1 subunit [60] . In addition, several of the NR2 NMDA receptor subunits can also be phosphoryated by PKC [61] . However, functional changes as a result of PKC phosphorlyation on NMDA receptors is complex, and in some cases, opposing actions from PKC phosphorylation have also been reported [57] . In fact, PKC appears to both enhance NMDA receptor peak currents via a tyrosine kinase cascade and depress NMDA receptor steady-state currents by a tyrosine kinase-independent mechanism [57] .
Given these mechanisms of synaptic plasticity and NMDA receptor function, the potential enhancement of LTP, by targeting NMDA receptor binding sites, appears to be an intuitive approach for drug discovery programs focused on memory improvement. However, in actuality this approach has turned out to be very difficult for reasons that are described in more detail below.
Effects of Calmodulin on NMDA Receptor Function
Calmodulin (CaM) is a Ca ++ -binding protein that is a key component of the Ca ++ second-messenger system and is known to play an important role in synaptic plasticity. Calcium can under normal circumstances enter the cytosol via the NMDA receptor channel (and by other routes). This influx is regulated in part by negative feedback mechanisms, thus limiting the amount of total [Ca ++ ] i . Past studies show that the NR1 subunit is targeted in this process and is inactivated by binding with CaM [62] [63] [64] . These studies showed that CaM binds to two sites (CBS1 and CBS2) on the C terminus of NR1 [63] . In particular, the NMDA receptor experiences a reduction in the mean open time and the opening frequency in recombinant NR1/NR2A channels [63] .
More recent data has been obtained from single channel recordings in so-called superclusters. Superclusters consist of a single receptor activation, and the sequence of openings and closings between the first channel opening after agonist binding, and the last channel opening before complete dissociation of agonist [65, 66] . In other words, superclusters are groups of openings in the data record that correspond to a single period during which molecules of glutamate are bound to the receptor. Using this approach, Rycroft and Gibb [64] found CaM (nanomolar concentrations) reduced the duration of supercluster channel openings. Also, total open time, the number of channel openings, and charge transfer per supercluster were all decreased by CaM, however, channel shut times were not affected by CaM [64] . Collectively, these results suggest that CaM inactivates NMDA receptor gating, shortens the NMDA excitatory post-synaptic current (EPSC), and significantly reduces calcium influx during synaptic transmission. These findings are thought important for synaptic plasticity since changes in channel open time influence the capacity of a nerve cell to detect simultaneous activity at more than one synapse, or in other words the modulation of synaptic integration and coincidence detection.
Redox Modulation of NMDA Receptors and Synaptic Plasticity
Gozlan et al. demonstrated in 1994 [67] the presence of a functional redox site on the NMDA receptor, which is presumed to be located extracellularly [68] . Studies have shown that NMDA receptor-mediated responses can be modulated by using oxidizing and reducing redox agents acting on this site. Additionally, NMDAassociated forms of LTP appear to be mediated by mechanisms that are sensitive to redox agents, such as 5,5'-dithio-bis-(2-nitrobenzoic acid) (DTNB) and tris(carboxyethyl)phosphine (TCEP). In a related study, DTNB (200 μM) was applied to pyramidal neurons where EPSCs were evoked in CA1 hippocampus by electrical stimulation of the stratum radiatum. Here it was found that DTNB inhibited NMDA-mediated EPSCs and this effect was not reversible with washout; however, the reducing agent, TCEP (200 μM) was able to reverse the effect of DTNB after 20 minutes of application [69] . This result suggested that redox agents modulate the presumed redox site on the NMDA receptor and that the NMDA receptor is in a reduced state in its native form.
In addition, DTNB was tested using LTP experimental paradigms where it was found DTNB totally blocked the induction and expression of NMDA-mediated LTP (ie., when 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) was used to block AMPA responses) [69] . Addditional administration of TCEP 30 minutes poststimulation in the same preparation elicited the expected potentiation of the EPSP slope. These results together with other work involving AMPA-mediated forms of LTP suggested that the redox site controls the hyperactivation of the NMDA receptors, but not its basal expression. In fact, the degree of NMDA receptor activation has been hypothesized to be controlled by oxidizing agents on the one end and reducing agents on the opposite end. In other words, increased NMDA receptor activation, decreasing Mg ++ concentrations and NMDA receptor hyperactivation are associated with reducing agents. According to this scheme [70] , plasticity of NMDA receptors, not only in physiological settings, but also in excitotoxic settings, appear to be regulated by the status of the redox site.
ROLE OF NMDA RECEPTORS IN EXCITOTOXICITY AND OTHER PATHOLOGICAL CONDITIONS Historical Perspective
The excitotoxic effects of glutamate were first observed in 1954 by Dr. Hayashi [8, 71] , and later in 1957 by Drs. Lucas and Newhouse in experiments in neonatal mice, which showed neurodegeneration in the retina after sodium L-glutamate treatment [72] . Subsequently, in 1969, John Olney observed that glutamate-induced pathology was not restricted to the retina, but occurred throughout the brain and coined the term excitotoxicity for the process he observed; he also showed glutamate antagonists could stop the neurotoxic cascade and limit the resulting neuropathology [73, 74] . These initial observations led to an explosion of research over the years that focused not only on the NMDA receptor, but also on a plethora of NMDA antagonists. These past studies initially suggested NMDA antagonists would be a "magic bullet" for limiting pathological downstream cascades linked to the excessive release of glutamate and the subsequent hyperactivation of NMDA receptors. Many excellent reviews have been already written on the role NMDA receptors in excitotoxicity and the reader is encouraged to read these [2, 21, 22, 33, [75] [76] [77] [78] .
Hyperactivation of the NMDA Receptor
Under normal conditions when the neuron is not firing, the NMDA receptor ion channel is blocked by physiological concentrations of Mg ++ [11] . Upon concurrent ligand binding (ie., glutamate and glycine) and membrane depolarization, the magnesium block is alleviated and the NMDA receptor/ion complex is activated thus allowing calcium and sodium to enter the cell through the NMDA channel. In addition, several endogenous mechanisms exist, such as glutamate transporters, calcium buffers, etc., which help regulate glutamate exposure, NMDA receptor activation, and [Ca ++ ] i levels so when glutamate-induced NMDA-mediated signaling occurs, it is not excessive, nor prolonged. However, as a result of acute brain injury (egs., hypoxia-ischemia, head trauma, status epilepticus) or other chronic pathologic conditions (egs., Alzheimer's disease, amyotrophic lateral sclerosis), the NMDA receptor can become hyperactivated and regulatory or endogenous neuroprotective mechanisms may fail. Therefore, when hyperactivation occurs, NMDA receptor mediated signaling initiates a host of excitotoxic processes, leading in some cases to neuronal cell death, which underlies not only acute neurodegenerative states, but also many chronic neurological conditions.
Hypoactivation of NMDA Receptors
Although controversial, hypoactivation of the NMDA receptor may also play a role in neurological disorders. In particular, John Olney and others [79, 80] have postulated that hypoactivation of NMDA receptors is a process that is involved in neurological disorders, ie., Alzheimer's disease (AD) and/or schizophrenia [79] . This idea is in contrast to many past studies involving schizophrenia research where NMDA receptor hyperactivation was thought to play the primary role. In AD, Olyney hypothesizes that NMDA receptor hypoactivation is preceded by NMDA receptor hyperactivation, or in other words, AD follows a two-stage process mediated by two separate mechanisms.
In the first stage, low levels of amyloid beta protein are thought to interact with NMDA receptors and increase the sensitivity of these receptors to glutamate thus causing hyperactivation of the NMDA receptors. As nerve cells degenerate, amyloid plaques deposit in the immediate neuronal and glial environment. Neuronal loss is not conspicuous since it may be restricted to just NMDA receptor bearing neurons and patients symptoms presumably are few if any.
The second stage is characterized by a persistent NMDA receptor hypoactivated state, which leads to widespread neurodegeneration. The pattern of neurodegeneration in this second stage is hypothesized to be dependent on the pattern of connections and signal transduction pathways within the neural network [79] . In other words, the loss of NMDA receptor bearing neurons in stage 1, is sufficient to release disinhibition processes (ie., abolish inhibitory tone) that in turn hyperstimulates several excitatory pathways, which terminate in posterior cingulated and retrosplenial cortical regions. As a result, the patient exhibits multiple cognitive disturbances during stage 2.
Effects of Chronic Ethanol Exposure on NMDA Receptors
Other examples of NMDA receptor modulation also exist and several studies have reported that intoxicating concentrations of ethanol inhibit NMDA receptor activity [81] [82] [83] . However, the effects of ethanol are complex and controversial and many adaptive responses appear at work. For example, one study has shown that NMDA receptors increase in number as an adaptive response to prolonged attenuation of NMDA receptor activity [83] . Additional studies have reported increases in NMDA receptor subunit and/or mRNA expression after ethanol exposure [84] , however, other investigations have also shown increases in NMDA receptor function without concomitant changes in NMDA receptor levels implying the presence of complex processes for the regulation of NMDA receptor function [85] .
One recent study has attempted to clarify these sorts of issues where it was reported that chronic ethanol exposure induces synaptic, but not extrasynaptic targeting of NMDA receptors. In this study [82] , the investigators used confocal imaging, immunohistochemistry, and electrophysiology to examine the effects of chronic ethanol exposure and found that ethanol may induce homeostatic changes in part through activity-dependent alterations in the synaptic trafficking of NMDA receptors. In other words, ethanol appears to differentially alter the expression and trafficking of NMDA receptors between distinct membrane domains.
AGE-DEPENDENT CHANGES IN NMDA RECEPTOR EX-PRESSION AND FUNCTION Early Development
NMDA subunits are differentially expressed during development [10, 12] . The NR1 subunit, however, is widely expressed throughout the CNS at all ages [86] . NR2B subunits are present in most rat brain regions at birth and increase over the first two weeks [29] . However, NR2A subunits are expressed slightly later and do not appear until the second week where their expression then increases rapidly [29] .
In general, there also appears to be a transient overproduction of NMDA binding sites during the second postnatal week in hippocampal tissue, which coincides with a transient overproduction of axonal neuroprojections [87] . In fact, the human infant brain is more susceptible to NMDA-mediated injury than AMPA-or kainate-mediated injury since NMDA receptor activity and expression increase in the infantile period, whereas AMPA and kainate receptors are not elevated until mid-gestation and decrease subsequently [88] . Other studies in neonates show that NMDA receptors have differences in their voltage dependencies that are hippocampal subfield specific [89] . Collectively, these differences in NMDA receptor structure and function at this early development stage appear to enhance network excitability.
Aging
In general, processes of aging negatively affect NMDA receptors. However, the age-dependent changes appear to be the result of several functional modifications, which are not regionally uniform. In addition, NMDA receptor binding site densities and electrophysiological characteristics have been shown to decrease in the NMDA receptor as a function of age more so than other glutamate receptor types [90, 91] . Furthermore, much of the literature points to losses in total binding sites where age-dependent declines in binding to one or more sites on the NMDA receptor complex and changes in the interactions between sites occur in both rodents and humans [91] . However, the cortex shows greater decreases in binding than the hippocampus as demonstrated by a number of past studies [92] [93] [94] [95] [96] . For example, aged rodents in general show greater decreases in binding to the NMDA binding site in cortical regions than the hippocampal formation [92] [93] [94] [95] [96] . However, age-related changes at the glycine binding site appear more variable and more studies are needed in this regard to fully characterize these potential changes. With regard to channel binding sites, there also appears to be an age-related decrease in the number of binding sites. Collectively, studies show that decreases in binding sites, when they occur, are in fact correlated with declines in memory performance [91] .
Other important age-related changes also occur such as decreases in the expression of NMDA subunits in older animals. For example, NR1 expression (ie., in distal dendrite of dentate granule cells) is decreased in aged monkeys compared to younger adults [97] . Other studies have also shown that mRNA expression for NR1 is decreased in older rats (ie., in the hypothalamus) [98] . Likewise, aged C57BL/6 mice have showed decreases of the epsilon2 subunit (rat NR2B) within the cortex and in dentate granule cells [99] . The meaning of these changes is not yet clear, however, subunit expression changes could alter the binding sites for glutamate or glycine.
Other reports have identified changes in the NMDA receptor/nitric oxide signaling pathway as a result of aging. Normal activation of the NMDA receptor induces nitric oxide (NO) synthesis, which leads to the formation of cyclic GMP. In particular, the NMDA/NO pathway has been shown to play a role in hippocampal LTP [42] . In some studies, NO and nitric oxide synthase (NOS) activity were found to decrease with aging as well as alterations in the NR1 subunit [100] ; however contrary evidence for NOS activity also exists. In the normal brain NOS inhibitors, such as L-NAME impair certain forms of memory, and therefore, reductions in NO and NOS in the aging brain would suggest the potential for agerelated memory impairment.
PAST AND PRESENT NMDA RECEPTOR ANTAGONISTS Classification of NMDA Receptor Antagonists
There are a number of widely used competitive, noncompetitive, and uncompetitive NMDA receptor antagonists. Competitive NMDA antagonists contend directly with glutamate for binding sites on the NMDA receptor and directly interact with the receptor. Competitive NMDA receptor antagonists tend to be longer chain amino acids, such as D-2-amino-7-phosphonovalerate (APV) and 3-(2-carboxypiperzin-4-yl) propyl-l-phosphonate (CPP) [101] . Unfortunately, noncompetitive and uncompetitive antagonists are often confused. Uncompetitive antagonists and noncompetitive antagonists both function by binding to sites in the channel. However, they are differentiated in several ways. A noncompetitive antagonist works allosterically at a binding site other than the agonist binding site. Whereas, an uncompetitive antagonist is defined (ie., by Stuart Lipton) as an inhibitor whose action is contingent upon prior activation of the receptor by the agonist [75] . Non-competitive antagonists include dizocilpine (MK-801) and phencyclidine (PCP), which cross the blood-brain barrier [101] . One of the most effective and seemingly safe uncompetitive NMDA antagonists to date is memantine.
Spider Venom and NMDA Receptor Antagonism
Several years ago, work by this author and former colleagues (NPS Pharmaceuticals and Pfizer, Inc.) found interesting bioactive properties on NMDA receptor function from a variety of spider venoms [6, 7] . In particular, chemical agents in the venom from local spiders (ie., Salt Lake City, UT) were found to paralyze insects by blocking glutamatergic neuromuscular transmission. Specifically, purified molecules from the venom, such as the arylalkylamines, were shown to act as reversible blockers of NMDA receptors in mammalian brain. The antagonism produced by these compounds at first resembled the characteristics of MK-801, but there were significant differences. Initially, MK-801 and the arylalkylamines appeared to be open channel blockers, given their agonistand voltage-dependence, but the arylalkylamines did not bind with the same high affinity as did MK-801. In one study, the actions of several well-known NMDA antagonists, such as AP5, AP7, ifenprodil, and MK-801 were compared against the arylalkylamines and it was found in rat CA1 hippocampal slices that the control compounds all blocked the induction of LTP, whereas the arylalkylamine did not block LTP [1] . Subsequently, it was shown that spider toxins of the arylalkylamine class, such as Joro toxin (JSTX-3), -agatoxin-489 (Agel-489), and philanthotoxin-433 ( -PhTX), argiotoxin-636, were noncompetitive NMDA antagonists that failed to block LTP in the rat hippocampal brain slice model [1] . This activity differentiated arylalkylamine toxins from all other classes of organic NMDA receptor antagonists at this time. This data [1] suggested that arylkylamine-induced open channel blockade was relieved much more readily than was the block elicited by compounds such as MK-801 or phencyclidine (PCP) (high-affinity open channel blockers).
Memantine
Memantine (1-amino-3,5-dimethyl-adamantane) was the first drug approved in the United States for the treatment of moderateto-severe AD [102] . It has also been used clinically for a number of indications for more than 20 years in Europe where its safety record has been excellent. Memantine can bind as a noncompetitive or uncompetitive antagonist that has low-to-moderate affinity for binding sites in the NMDA channel. It is also exhibits a rapid voltagedependent interaction with the NMDA channel, and therefore can dissociate from the NMDA channel for short periods of time during normal physiologic processes. Memantine interacts with binding sites in the channel complex and in so doing acts in some ways like magnesium (Mg ++ ) [103, 104] . However, unlike Mg ++ memantine does not leave the NMDA channel during pathologic hyperactivation [105] . If one compares the blocking kinetics of memantine to MK-801 and Mg ++ in cultured superior colliculus neurons using whole cell patch clamp methods, memantine shows kinetics and voltage dependency between those of Mg ++ and MK-801 [105] . Memantine (16 μmol/L) has also shown faster on/off receptor blockade kinetics in current responses to NMDA administration (200 μmol/L) in cultured neurons than phencyclidine (3.3 μmol/L) and comparable kinetics (10 μmol/L) to ketamine and dextromethorphan (10 μmol/L) [102] . Memantine (5-50 mg/kg) has been shown to be neuroprotective in several animal models of brain injury including models of ischemic stroke and traumatic brain injury. Other studies have also reported that memantine stimulates brain-derived neurotrophic factor (BDNF), an agent previously reported to promote neuronal survival. Collectively, these studies demonstrate the advantages of using memantine given its suspected NMDA noncompetitive and uncompetitive blocking mechanisms.
In support of these mechanisms, studies by Chen and Lipton [106, 107] , Antonov and Johnson [108] , Bresink et al. [109] , Blannpied et al. [110] , Danysz and Parsons [111] , and Sobolevsky et al. [112] , to name a few, suggest that memantine interacted with the NMDA receptor complex by binding at or near the so-called Mg ++ binding site within the NMDA channel where two specific sites for memantine binding have been hypothesized. In one case, memantine was demonstrated to bind noncompetitively at the L651 residue of NR1 (M3 segment), a more shallow site nearer the mouth of the channel [107, 113] . In the other case, memantine can bind directly with a Mg ++ binding site, a slightly deeper site within the channel, in an uncompetitive manner [107, 113] .
While this may not seem significant, the distinction between these two binding sites is actually profound since the uncompetitive blockade mechanism at the deeper site is thought largely responsible for attenuating the hyperactivation of the NMDA receptor without interfering with normal NMDA mediated signaling due to the rapid off-rate at this binding site. In fact, memantine appears to block uncompetitively at low concentrations (ie., with high affinity) and also noncompetitively (ie., with low-affinity) at higher concentrations [25] . Binding at the shallow nonspecific site may allow dissociation of the compound in either the open or closed channel conformation; whereas binding at the more specific deeper site (Nsite asparagines in the M2 region of NR1 subunit) is associated with the narrower portion of the channel, the channel's selectivity filter, and a more pronounced partial trapping of memantine in the channel. However, given that memantine has a faster off-rate at the deeper site allows it to possess an excellent clinical drug profile. Therefore, the beneficial effects of memantine appear to be sufficiently explained by the mechanistic actions of this drug at two binding sites, given that this drug experimentally demonstrates a mixture of biophysical properties of both sites [113] .
Selective Subunit Antagonists
Targeting specific subtypes of the NMDA receptor continues to be a popular strategy [114] for achieving therapeutic benefit. Some investigators have divided the domain structure of the NMDA receptor complex into three main regions, where each is considered a functional module [114] . The extracellular amino terminal domain, which contains R1 and R2 segments, are sensitive to modulators such as Zn ++ or ifenprodil and bind in a noncompetitive manner.
Agents such as NMDA, AP5, CPP, and glutamate, on the other hand, bind competitively to S1 and S2 segments of the NR2 subunit. In the channel pore, or transmembrane domain, each subunit contains a pore region composed of 3 helices (M1, M3 and M4) and a re-entrant helical loop (M2 loop). Compounds that bind in this region can be uncompetitive antagonists, such as MK-801 or memantine, or the endogenous blocker, magnesium. To this end, several potent and selective NR2B subunit antagonists have been tested, most of which are neuroprotective in animal models, and produce minimal side effects at maximally neuroprotective doses (eg, CP-101606; [115, 116] ). Importantly, the improved side effect profile of NR2B-selective agents has encouraged the initiation of clinical trials for several neurological disorders in human patients. The effectiveness of these compounds seems to be related to the fact that NR2B receptors are extrasynaptic in location and that differentially located NMDA receptors once activated initiate negative effects on neuronal survival [115, 116] . For example, stimulation of extrasynaptic NMDA receptors elicited a loss of mitochondrial membrane potential, which is associated with glutamate-induced toxicity. On the other hand, synaptic NMDA receptor activation appears to have an anti-apoptotic activity. These observations suggest that specific antagonism of extrasynaptic NR2B receptors may have effective neuroprotective qualities for excitotoxic processes without effecting normal synaptic NR1/NR2A and NR1/ NR2C mediated-signaling events.
Another potential mechanism involves tyrosine phosphorylation of the NR2B subunit [115, 116] . The NMDA receptor is subject to phosphorylation by a variety of different kinases. In fact, the NR2B subunit in a major target for tyrosine-phosphorylation. Once phosphorylation occurs, NMDA currents are potentiated or increase, leading to the upregulation of physiological activity and/or alteration of synaptic strength.
Dopamine/NMDA Receptor Interactions
Several past studies have also investigated NMDA/D1 receptor complexes as a potential drug target where the D1 receptor, the most common dopamine (DA) receptor, has been reported to interact with NMDA receptors in several ways. First, dysfunction of DA receptor signaling in certain psychiatric disorders, such as schizophrenia has long been suspected, but interactions of DA receptors with NMDA receptors in affective disorders and other disorders is a more contemporary idea. For example, studies show that DA potentiates NMDA receptor-mediated currents by activating D1 receptors [117] . DA stimulation of the D1 receptor has also been found to be required under some circumstances for NMDA-mediated LTP [117] . In support of DA and NMDA interactions, past data also show that blockade of NMDA receptors induces symptoms of schizophrenia [118, 119] . In addition, NMDA receptor antagonists potentiate the effects of L-DOPA in animal models of Parkinson's disease [120] . More recent studies also have shown that D1 receptor stimulation results in the rapid translocation of NMDA receptors to sites on the postsynaptic membrane [121] . Collectively, these investigations indicate that dopamine-glutamate receptor interactions may be alternative drug targets for drug development in neurological and psychiatric disorders (also see review [122] ).
Side Effects From NMDA Antagonism
In past clinical trials, a range of NMDA receptor antagonists were tested where most were reported to function by competing with glutamate for binding to the NMDA receptor, or by blocking sites within the NMDA receptor channel. The problem that emerged from these trials was that prolonged antagonism of the NMDA receptor proved to be detrimental. The agents, while attenuating excitotoxic processes, also prevented normal signal transduction and interfered with basic physiological functioning [21] . Administration of compounds, such as MK-801, caused hallucinations, psychosis or even coma in many cases. Other side effects from NMDA receptor antagonists also were manifested, which included deterioration of motor function (in genetic absence epilepsy rats), abnormal axonal arborization (in neonatal rats administered AP5), and effects on learning (in monkeys) from chronic developmental exposure to remacemide [19, 20, [123] [124] [125] [126] . Clinical trials involving first generation NMDA receptor antagonists that were administered for stroke or traumatic brain injury also failed for additional reasons related to deficient pharmacokinetics, inability to reach effective concentrations in key target areas, short neuroprotective time windows, inappropriate receptor subunit selectivity, and poor design of clinical trials, to name a few [127] .
NMDA-Receptor Mediated Survival Mechanisms
Synaptic activity mediated by NMDA receptors has also been reported to promote the survival of nerve cells [21, 127] . Given these findings, the total blockade of NMDA-receptor-mediated synaptic transmission could be unfavorable under conditions of stroke, trauma, status epilepticus or chronic conditions, such as Alzheimer's dementia, where endogenous mechanisms of neuroprotection, including NMDA receptor activation, would be important. For instance, it is known that activation of NMDA receptors leads to Ca ++ entry through its channel, which in turn leads to the activation of extracellular signal-regulated kinase (ERK1/2) and the activation of Ca ++ -calmodulin (CaM) kinase pathways. The activation of these pathways occurs along different time scales, but both are known to lead to cAMP-response-element-binding protein (CREB) phosphorylation. This is noteworthy since CREB phosphorylation is linked to gene transcription, which is not only essential for converting short-term memory to long-term memory, but also important for cell survival. Supporting this theory is the observation that CREB can be activated by stressful stimuli such as hypoxiaischemia. In addition, animals that lack CREB show widespread neuronal apoptosis in the CNS during developmental periods. Therefore, CREB activation may contribute to ischemic tolerance for transient episodes of hypoxia-ischemia and also may help to regulate appropriate cell number. Given this, investigators [127] have suggested that too much glutamate and abnormal increases in Ca ++ entry kills neurons immediately after injury, but that glutamate may also facilitate cell repair shortly afterward. Collectively, this data suggest that NMDA receptor-mediated signaling can be linked to either neuroprotective or neurodegenerative signaling pathways that are condition-specific, thus creating a dichotomous signaling system that has direct clinical implications.
CONCLUSIONS
Numerous studies demonstrated that specific subunit combinations convey distinct properties in the NMDA receptor. Given this, several NMDA receptor mutant mouse models were engineered to determine the effect of genetic alterations on NMDA receptor function. These investigations were instrumental in providing a foundation for our current understanding of biophysical properties, the molecular biology of the NMDA receptor/ion complex, and also for investigations probing synaptic integration, plasticity, excitotoxicity, development, aging, and memory, to name a few.
Moreover, in vitro and in vivo studies showed in a complementary way that LTP leads to a long-lasting increase in the strength of synaptic transmission, which in most cases is NMDA-mediated. Furthermore, PKC, PKA, and calcium/calmodulin-dependent kinases and phosphatases, etc. were shown to regulate NMDA receptor function illuminating a complex picture for NMDA-dependent processes of LTP and memory encoding.
Other research reported that plasticity of NMDA receptors appeared to be regulated by many different and sometimes overlapping mechanisms in both physiological and excitotoxic settings. In fact, a variety of binding sites on the NMDA receptor were postulated in early studies to be potential targets for attenuating hyperactivation leading to excitotoxicity. To this end, an explosion of research over the years focused on a plethora of NMDA competitive antagonists that were hoped to limit unwanted hyperactivation of the NMDA receptor. Unfortunately, NMDA receptor-mediated signaling turned out to be more complicated than anticipated where critical balances between too much NMDA signaling and too little signaling were realized in drug-development contexts.
The good news, of course, was that compounds like memantine were found in part to have a fast off-rate and proved safe thus demonstrating an excellent clinical drug profile for conditions such as Alzheimer's disease. Other strategies are also now being tested that focus on NMDA-mediated mechanisms, which are alternative to direct competitive antagonism of the NMDA receptor binding site. Given the complexities of NMDA receptor-mediated dichotomous signaling, one can only begin to imagine the potential for intervention in these signaling pathways. This review has highlighted only some of the important advances in the NMDA receptor field, but surely there will be many more in the near future.
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